Antiprogestin Drugs: Ethical Issues
Law, Medicine and Health Care. 1992 Fall; 20(3): 215-219.
Does the prospect of introducing RU 486 into the United States pose any unique ethical issues? Or are the ethical questions raised by antiprogestins similar to those that arise when any new medical technology comes along? The short answer is that the ethical issues are not new or different, but the politics of abortion can seduce us into thinking that antiprogestins bear ethical hazards of a novel sort. One transcending ethical question stands before us: Would it be the right thing to do to introduce RU 486 into the United States today? The deceptive simplicity of that question requires further analysis. "What is the right thing to do?" breaks down into several component questions: Would introduction of RU 486 into the U.S. produce more benefits than harms? Would it enhance the autonomy of women? Would it afford women the prospect for greater privacy? Would RU 486 increase access for women in this country to a means of terminating unwanted pregnancy? The answers to these questions all depend on facts. Good ethics begins with good facts.
Abortion; Attitudes; Autonomy; Counseling; Consent; Drugs; Ethical Analysis; Ethics; Evaluation; Freedom; Health; Health Facilities; Informed Consent; Justice; Morality; Politics; Pregnant Women; Privacy; Professional Patient Relationship; Psychological Stress; Public Policy; Pregnancy; Reproduction; Rights; Risks and Benefits; Surgery; Technology; Utilitarianism; Women's Health; Women's Rights;
Showing items related by title, author, creator and subject.
Cook, Rebecca J.; Grimes, David A. (1992)The antiprogestin drug mifepristone, popularly known as RU 486, provides women with the choice of abortion by nonsurgical means. Nonsurgical abortion is coming to be described as medical abortion, in contrast to surgical ...